The registry will capture prospective data on patients receiving pain management for chronic pain due to knee osteoarthritis (OA) or pain optimization for knee arthroplasty due to knee OA. The OA pain therapies may include cryo nerve block, radiofrequency ablation (RFA), intra-articular (IA) corticosteroids, viscosupplementation, opioids, and others (e.g., non-steroidal anti-inflammatory drugs \[NSAIDs\]).
Knee Osteoarthritis
The registry will capture prospective data on patients receiving pain management for chronic pain due to knee osteoarthritis (OA) or pain optimization for knee arthroplasty due to knee OA. The OA pain therapies may include cryo nerve block, radiofrequency ablation (RFA), intra-articular (IA) corticosteroids, viscosupplementation, opioids, and others (e.g., non-steroidal anti-inflammatory drugs \[NSAIDs\]).
Innovations in Genicular Outcomes Registry
-
Orthopedic Education and Research Institute of So Ca (Hoag), Irvine, California, United States, 92618
Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
MidState Orthopedics and Sports Medicine, Alexandria, Louisiana, United States, 71301
Louisiana State University /Ochsner, New Orleans, Louisiana, United States, 70112
Sinai Hospital of Baltimore, Baltimore, Maryland, United States, 21215
Henry M Jackson Foundation for the Advancement of Military Medicine/Walter Reed National Military Medical Center, Bethesda, Maryland, United States, 20889
OrthoNebraska Clinics, Omaha, Nebraska, United States, 68144
Jersey City Medical Center, Jersey City, New Jersey, United States, 07302
Genesee Orthopedics and Plastic Surgery (St. Elizabeth Med Center/ Apex Surgical Center), New Hartford, New York, United States, 13413
Blue Nine Systems, Asheville, North Carolina, United States, 28801
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to
ALL
No
Pacira Pharmaceuticals, Inc,
2025-03-31